Company Profiles
Target Profiles
Product Profiles
Latest Articles
Commentaries
Deals
Distillery
Emerging Companies
Finance
Politics, Policy & Law
Product Development
Regulation
Targets & Mechanisms
Tools & Techniques
Company Profiles
Target Profiles
Product Profiles
China Healthcare Summit
Bio€quity Europe
Explore BCIQ profiles by entering a product name.
REQUEST A FREE TRIAL
Product
Deals
Articles
BioCentury
|
Aug 20, 2022
Deals
How Ultragenyx delivered win for biotech venture philanthropy via GeneTx deal
Rare disease company invested in a spinout of a non-profit that was making science decisions, not just writing checks
Read More
BioCentury
|
Aug 31, 2021
Regulation
New surrogate endpoints need resolution of ‘reasonably likely’
Regulatory clarity, consistency, key to taking accelerated approval outside of cancer
Read More
BioCentury
|
Aug 30, 2021
Regulation
The promise and problems of expediting drug approvals
Overview of status of expedited approval pathways sets stage for BioCentury’s 29th Back to School
Read More
BioCentury
|
Dec 8, 2017
Product Development
Making of Mepsevii
Why Ultragenyx developed Mepsevii for ultra-rare indication MPS VII
Read More
BioCentury
|
Mar 28, 2016
Strategy
Canbridge can-can
Why Aveo's AV-203 is leading Canbridge to venture outside Asia
Read More
BioCentury
|
Dec 8, 2014
Strategy
BioMarin bulks up
Why BioMarin buying Prosensa despite drisapersen Phase III miss in DMD
Read More
BioCentury
|
Oct 16, 2014
Distillery Therapeutics
Indication: Endocrine/metabolic disease
Read More
BioCentury
|
Sep 18, 2014
Distillery Therapeutics
Indication: Endocrine/metabolic disease
Read More
BioCentury
|
Jun 16, 2014
Regulation
Signal crossing
Caregivers want more real-world, caregiver-reported outcomes in inborn errors
Read More
BioCentury
|
Mar 31, 2014
Regulation
Viral crossroads
Hardy case shows flaws in compassionate use system, provides catalyst for change
Read More
Items per page:
10
1 - 10 of 174